| Certificates/Standards: | N; |
| Monthly Output: | Not provided |
| Regional: | Not provided |
| Packaging Information: | Not provided |
| Mode Of Payment: | Not provided |
| Delivery Lead Time: | Not provided |
| Main Sales Markets: | North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa |
| Sample Provided: | No |
| Sample Policy: | Not provided |
| Minimum Quantity: | Not provided |
BioCatSyn translates R&D results from East China University of Science and Technology into patent-backed technologies for scalable production of high-purity squalene, meeting European Pharmacopoeia standards. It has already secured DMF (Drug Master File) registration with the US FDA and is now widely used in medical fields such as vaccines.
Through its unique patented technology, BioCatSyncan produce 1 kilogram of high-purity squalene from 3 kilograms of corn, making squalene’s applications in the personal care sector greener and more environmentally friendly.